中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (5): 387-399.doi: 10.35541/cjd.20230746
中国医师协会皮肤科医师分会
收稿日期:2023-12-15
修回日期:2024-02-24
发布日期:2024-04-30
通讯作者:
郝飞；王芳；宋志强
E-mail:haofei62@126.com；wangf78@mail.sysu.edu.cn;drsongzq@hotmail.com
China Dermatologist Association
Received:2023-12-15
Revised:2024-02-24
Published:2024-04-30
Contact:
Hao Fei; Wang Fang; Song Zhiqiang
E-mail:haofei62@126.com；wangf78@mail.sysu.edu.cn;drsongzq@hotmail.com
摘要： 【摘要】 慢性瘙痒是多种疾病的共同症状，严重影响患者的生活质量。瘙痒发生机制复杂，病因诊断与治疗常面临挑战。为提升我国临床医生对慢性瘙痒的认识，规范诊治行为，中国医师协会皮肤科医师分会组织国内部分专家，在我国《慢性瘙痒管理指南（2018版）》的基础上，基于国内外研究现状与进展，对慢性瘙痒的分类、病因及机制等方面进行了更新，并通过德尔菲法广泛征询专家意见，为慢性瘙痒的病因诊断与治疗方案提供专家意见与循证医学证据。
中国医师协会皮肤科医师分会. [开放获取] 慢性瘙痒管理指南（2024版）[J]. 中华皮肤科杂志, 2024,57(5):387-399. doi:10.35541/cjd.20230746
China Dermatologist Association. Guidelines for the management of chronic pruritus （2024）[J]. Chinese Journal of Dermatology, 2024, 57(5): 387-399.doi:10.35541/cjd.20230746
| ［1］ | Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch［J］. Nat Rev Neurosci, 2006,7（7）:535⁃547. doi: 10.1038/nrn1950. |
| ［2］ | 中国医师协会皮肤科分会变态反应性疾病专业委员会. 慢性瘙痒管理指南（2018版）［J］. 中华皮肤科杂志, 2018,51（7）:481⁃485. doi: 10.3760/cma.j.issn.0412⁃4030.2018.07.001. |
| ［3］ | Mack MR, Kim BS. The itch⁃scratch cycle: a neuroimmune perspective［J］. Trends Immunol, 2018,39（12）:980⁃991. doi: 10.1016/j.it.2018.10.001. |
| ［4］ | Ständer S, Zeidler C, Augustin M, et al. S2k guideline: diagnosis and treatment of chronic pruritus［J］. J Dtsch Dermatol Ges, 2022,20（10）:1387⁃1402. doi: 10.1111/ddg.14830. |
| ［5］ | Matterne U, Strassner T, Apfelbacher CJ, et al. Measuring the prevalence of chronic itch in the general population: development and validation of a questionnaire for use in large⁃scale studies［J］. Acta Derm Venereol, 2009,89（3）:250⁃256. doi: 10.2340/00015555⁃0641. |
| ［6］ | Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity［J］. Acta Derm Venereol, 2009,89（4）:339⁃350. doi: 10.2340/00015555⁃0662. |
| ［7］ | Dalgard F, Lien L, Dalen I. Itch in the community: associations with psychosocial factors among adults［J］. J Eur Acad Dermatol Venereol, 2007,21（9）:1215⁃1219. doi: 10.1111/j.1468⁃3083.2007.02234.x. |
| ［8］ | Matterne U, Apfelbacher CJ, Vogelgsang L, et al. Incidence and determinants of chronic pruritus: a population⁃based cohort study［J］. Acta Derm Venereol, 2013,93（5）:532⁃537. doi: 10.2340/00015555⁃1572. |
| ［9］ | Ständer S, Schäfer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross⁃sectional study in a sample working population of 11,730［J］. Dermatology, 2010,221（3）:229⁃235. doi: 10.1159/000319862. |
| ［10］ | Ju Y, Pei H, Kang N, et al. Prevalence and potential risk factors of chronic pruritus among community middle⁃aged and older population in Beijing, China［J］. J Eur Acad Dermatol Venereol, 2022,36（7）:1074⁃1079. doi: 10.1111/jdv.18041. |
| ［11］ | Matterne U, Apfelbacher CJ, Loerbroks A, et al. Prevalence, correlates and characteristics of chronic pruritus: a population⁃based cross⁃sectional study［J］. Acta Derm Venereol, 2011,91（6）:674⁃679. doi: 10.2340/00015555⁃1159. |
| ［12］ | Yosipovitch G, Goon AT, Wee J, et al. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus［J］. Int J Dermatol, 2002,41（4）:212⁃216. doi: 10.1046/j.1365⁃4362.2002.01460.x. |
| ［13］ | Szepietowski JC, Salomon J. Uremic pruritus: still an important clinical problem［J］. J Am Acad Dermatol, 2004,51（5）:842⁃843. doi: 10.1016/j.jaad.2004.04.003. |
| ［14］ | Akolo C, Ukoli CO, Ladep GN, et al. The clinical features of HIV/AIDS at presentation at the Jos University Teaching Hospital［J］. Niger J Med, 2008,17（1）:83⁃87. doi: 10.4314/njm.v17i1.37363. |
| ［15］ | Mazeh D, Melamed Y, Cholostoy A, et al. Itching in the psychiatric ward［J］. Acta Derm Venereol, 2008,88（2）:128⁃131. doi: 10.2340/00015555⁃0406. |
| ［16］ | Dalgard FJ, Svensson Å, Halvorsen JA, et al. Itch and mental health in dermatological patients across Europe: a cross⁃sectional study in 13 countries［J］. J Invest Dermatol, 2020,140（3）:568⁃573. doi: 10.1016/j.jid.2019.05.034. |
| ［17］ | Tripathi R, Knusel KD, Ezaldein HH, et al. The cost of an itch: a nationally representative retrospective cohort study of pruritus⁃associated health care expenditure in the United States［J］. J Am Acad Dermatol, 2019,80（3）:810⁃813. doi: 10.1016/j.jaad.2018.10.025. |
| ［18］ | Chen XJ, Sun YG. Central circuit mechanisms of itch［J］. Nat Commun, 2020,11（1）:3052. doi: 10.1038/s41467⁃020⁃16859⁃5. |
| ［19］ | Wang F, Yang TB, Kim BS. The return of the mast cell: new roles in neuroimmune itch biology［J］. J Invest Dermatol, 2020,140（5）:945⁃951. doi: 10.1016/j.jid.2019.12.011. |
| ［20］ | Saini SS, Kaplan AP. Chronic spontaneous urticaria: the Devil′s itch［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1097⁃1106. doi: 10.1016/j.jaip.2018.04.013. |
| ［21］ | Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co⁃opt classical immune signaling pathways to mediate chronic itch［J］. Cell, 2017,171（1）:217⁃228.e13. doi: 10.1016/j.cell.2017.08.006. |
| ［22］ | Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron⁃expressed IL⁃31 receptor mediates T helper cell⁃dependent itch: involvement of TRPV1 and TRPA1［J］. J Allergy Clin Immunol, 2014,133（2）:448⁃460. doi: 10.1016/j.jaci.2013.10.048. |
| ［23］ | Dehner C, Chen L, Kim B, et al. Chronic itch of unknown origin is associated with an enhanced Th2 skin immune profile［J］. Am J Dermatopathol, 2021,43（11）:773⁃775. doi: 10.1097/DAD. 0000000000001902. |
| ［24］ | Wang F, Trier AM, Li F, et al. A basophil⁃neuronal axis promotes itch［J］. Cell, 2021,184（2）:422⁃440.e17. doi: 10.1016/j.cell.2020.12.033. |
| ［25］ | Liu B, Tai Y, Achanta S, et al. IL⁃33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy［J］. Proc Natl Acad Sci U S A, 2016,113（47）:E7572⁃E7579. doi: 10.1073/pnas.1606608113. |
| ［26］ | Andoh T, Kuraishi Y. Intradermal leukotriene B4, but not prostaglandin E2, induces itch⁃associated responses in mice［J］. Eur J Pharmacol, 1998,353（1）:93⁃96. doi: 10.1016/s0014⁃2999（98）00440⁃3. |
| ［27］ | Meixiong J, Vasavda C, Snyder SH, et al. MRGPRX4 is a G protein⁃coupled receptor activated by bile acids that may contribute to cholestatic pruritus［J］. Proc Natl Acad Sci U S A, 2019,116（21）:10525⁃10530. doi: 10.1073/pnas.1903316116. |
| ［28］ | Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid⁃induced itch and analgesia［J］. J Clin Invest, 2013,123（4）:1513⁃1530. doi: 10.1172/JCI64551. |
| ［29］ | Liu Q, Tang Z, Surdenikova L, et al. Sensory neuron⁃specific GPCR Mrgprs are itch receptors mediating chloroquine⁃induced pruritus［J］. Cell, 2009,139（7）:1353⁃1365. doi: 10.1016/j.cell.2009.11.034. |
| ［30］ | Lin Z, Chen Q, Lee M, et al. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome［J］. Am J Hum Genet, 2012,90（3）:558⁃564. doi: 10.1016/j.ajhg.2012.02.006. |
| ［31］ | Zhao J, Munanairi A, Liu XY, et al. PAR2 mediates itch via TRPV3 signaling in keratinocytes［J］. J Invest Dermatol, 2020,140（8）:1524⁃1532. doi: 10.1016/j.jid.2020.01.012. |
| ［32］ | Akiyama T, Tominaga M, Takamori K, et al. Roles of glutamate, substance P, and gastrin⁃releasing peptide as spinal neurotransmitters of histaminergic and nonhistaminergic itch［J］. Pain, 2014,155（1）:80⁃92. doi: 10.1016/j.pain.2013.09.011. |
| ［33］ | Sun YG, Chen ZF. A gastrin⁃releasing peptide receptor mediates the itch sensation in the spinal cord［J］. Nature, 2007,448（7154）:700⁃703. doi: 10.1038/nature06029. |
| ［34］ | Mishra SK, Hoon MA. The cells and circuitry for itch responses in mice［J］. Science, 2013,340（6135）:968⁃971. doi: 10.1126/science.1233765. |
| ［35］ | Carstens EE, Carstens MI, Simons CT, et al. Dorsal horn neurons expressing NK⁃1 receptors mediate scratching in rats［J］. Neuroreport, 2010,21（4）:303⁃308. doi: 10.1097/WNR.0b013e328337310a. |
| ［36］ | Kim BS, Inan S, Ständer S, et al. Role of kappa⁃opioid and mu⁃opioid receptors in pruritus: peripheral and central itch circuits［J］. Exp Dermatol, 2022,31（12）:1900⁃1907. doi: 10.1111/exd.14669. |
| ［37］ | Zhao ZQ, Liu XY, Jeffry J, et al. Descending control of itch transmission by the serotonergic system via 5⁃HT1A⁃facilitated GRP⁃GRPR signaling［J］. Neuron, 2014,84（4）:821⁃834. doi: 10.1016/j.neuron.2014.10.003. |
| ［38］ | Mu D, Sun YG. Circuit mechanisms of itch in the brain［J］. J Invest Dermatol, 2022,142（1）:23⁃30. doi: 10.1016/j.jid.2021. 09.022. |
| ［39］ | Auyeung KL, Jenkins BA, Kim BS. Clinical management of neuropathic itch［J］. JAMA Dermatol, 2023,159（12）:1391⁃1392. doi: 10.1001/jamadermatol.2023.3384. |
| ［40］ | Lepping P, Huber M, Freudenmann RW. How to approach delusional infestation［J］. BMJ, 2015,350:h1328. doi: 10.1136/bmj.h1328. |
| ［41］ | Pereira MP, Farcas A, Zeidler C, et al. Chronic pruritus of unknown origin: clinical profile and disease⁃related burden［J］. Acta Derm Venereol, 2021,101（9）:adv00550. doi: 10.2340/00015555⁃3892. |
| ［42］ | Erickson S, Kim BS. Research techniques made simple: itch measurement in clinical trials［J］. J Invest Dermatol, 2019,139（2）:264⁃269.e1. doi: 10.1016/j.jid.2018.12.004. |
| ［43］ | Yosipovitch G, Gooderham MJ, Ständer S, et al. Interpreting the relationship among itch, sleep, and work productivity in patients with moderate⁃to⁃severe atopic dermatitis: a post hoc analysis of JADE MONO⁃2［J］. Am J Clin Dermatol, 2024,25（1）:127⁃138. doi: 10.1007/s40257⁃023⁃00810⁃7. |
| ［44］ | Krajnik M, Zylicz Z. Pruritus in advanced internal diseases. Pathogenesis and treatment［J］. Neth J Med, 2001,58（1）:27⁃40. doi: 10.1016/s0300⁃2977（00）00084⁃x. |
| ［45］ | Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T⁃cell lymphoma: a review［J］. J Am Acad Dermatol, 2012,67（4）:760⁃768. doi: 10.1016/j.jaad.2011.12.021. |
| ［46］ | Gudmundsdóttir SL, Ballarini T, Ámundadóttir ML, et al. Clinical efficacy of a digital intervention for patients with atopic dermatitis: a prospective single⁃center study［J］. Dermatol Ther （Heidelb）, 2022,12（11）:2601⁃2611. doi: 10.1007/s13555⁃022⁃00821⁃y. |
| ［47］ | 中国医师协会皮肤科医师分会. 保湿润肤类产品应用指导专家共识（2023版）［J］. 中华皮肤科杂志, 2023,56（8）:711⁃717. doi: 10.35541/cjd.20230133. |
| ［48］ | 中国中西医结合学会皮肤性病专业委员会. 规范外用糖皮质激素类药物专家共识［J］. 中华皮肤科杂志, 2015,48（2）:73⁃75. doi: 10.3760/cma.j.issn.0412⁃4030.2015. 02.001. |
| ［49］ | Ang⁃Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials［J］. Expert Rev Clin Pharmacol, 2012,5（1）:91⁃97. doi: 10.1586/ecp.11.68. |
| ［50］ | Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: partⅠ, efficacy［J］. J Am Acad Dermatol, 2001,44（1 Suppl）:S28⁃S38. doi: 10.1067/mjd.2001.109810. |
| ［51］ | Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 （PDE4） inhibitor for the topical treatment of atopic dermatitis （AD） in children and adults［J］. J Am Acad Dermatol, 2016,75（3）:494⁃503.e6. doi: 10.1016/j.jaad.2016.05.046. |
| ［52］ | Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose⁃ranging, vehicle⁃ and active⁃controlled study［J］. J Am Acad Dermatol, 2020,82（6）:1305⁃1313. doi: 10.1016/j.jaad.2020.02.009. |
| ［53］ | Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double⁃blind studies［J］. J Am Acad Dermatol, 2021,85（4）:863⁃872. doi: 10.1016/j.jaad.2021.04.085. |
| ［54］ | Bauer M, Schwameis R, Scherzer T, et al. A double⁃blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine⁃induced pruritus and UVB⁃light induced slight sunburn pain［J］. J Dermatolog Treat, 2015,26（4）:367⁃372. doi: 10.3109/09546634.2014.992384. |
| ［55］ | Tarng DC, Cho YL, Liu HN, et al. Hemodialysis⁃related pruritus: a double⁃blind, placebo⁃controlled, crossover study of capsaicin 0.025% cream［J］. Nephron, 1996,72（4）:617⁃622. doi: 10.1159/000188949. |
| ［56］ | Lysy J, Sistiery⁃Ittah M, Israelit Y, et al. Topical capsaicin⁃⁃a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study［J］. Gut, 2003,52（9）:1323⁃1326. doi: 10.1136/gut.52.9.1323. |
| ［57］ | Panahi Y, Davoodi SM, Khalili H, et al. Phenol and menthol in the treatment of chronic skin lesions following mustard gas exposure［J］. Singapore Med J, 2007,48（5）:392⁃395. |
| ［58］ | Macpherson LJ, Hwang SW, Miyamoto T, et al. More than cool: promiscuous relationships of menthol and other sensory compounds［J］. Mol Cell Neurosci, 2006,32（4）:335⁃343. doi: 10.1016/j.mcn.2006.05.005. |
| ［59］ | High⁃dose antihistamines for chronic spontaneous urticaria in adults［J］. Drug Ther Bull, 2018,56（4）:45⁃48. doi: 10.1136/dtb.2018.4.0614. |
| ［60］ | Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double⁃blind, placebo⁃controlled phase 3 trials［J］. Nat Med, 2023,29（5）:1180⁃1190. doi: 10.1038/s41591⁃023⁃02320⁃9. |
| ［61］ | Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2014,371（2）:130⁃139. doi: 10.1056/NEJMoa1314768. |
| ［62］ | Blauvelt A, de Bruin⁃Weller M, Gooderham M, et al. Long⁃term management of moderate⁃to⁃severe atopic dermatitis with dupilumab and concomitant topical corticosteroids （LIBERTY AD CHRONOS）: a 1⁃year, randomised, double⁃blinded, placebo⁃controlled, phase 3 trial［J］. Lancet, 2017,389（10086）:2287⁃2303. doi: 10.1016/S0140⁃6736（17）31191⁃1. |
| ［63］ | Jeon J, Wang F, Badic A, et al. Treatment of patients with chronic pruritus of unknown origin with dupilumab［J］. J Dermatolog Treat, 2022,33（3）:1754⁃1757. doi: 10.1080/09546634.2021.1880542. |
| ［64］ | Zhai LL, Savage KT, Qiu CC, et al. Chronic pruritus responding to dupilumab⁃a case series［J］. Medicines （Basel）, 2019,6（3）:72. doi: 10.3390/medicines6030072. |
| ［65］ | Wang SH, Shan Y, Li SZ, et al. Anti⁃interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1⁃year follow⁃up: a monocentric real⁃world study［J］. Front Immunol, 2023,14:1165106. doi: 10.3389/fimmu.2023.1165106. |
| ［66］ | Bai F, Li GG, Liu Q, et al. Short⁃term efficacy and safety of IL⁃17, IL⁃12/23, and IL⁃23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta⁃analysis of randomized controlled trials［J］. J Immunol Res, 2019,2019:2546161. doi: 10.1155/2019/2546161. |
| ［67］ | Sbidian E, Chaimani A, Garcia⁃Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta⁃analysis［J］. Cochrane Database Syst Rev, 2017,12（12）:CD011535. doi: 10.1002/14651858.CD011535.pub2. |
| ［68］ | Thyssen JP, Yosipovitch G, Paul C, et al. Patient⁃reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate⁃to⁃severe atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2022,36（3）:434⁃443. doi: 10.1111/jdv.17813. |
| ［69］ | Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2021,157（9）:1047⁃1055. doi: 10.1001/jamadermatol. 2021.3023. |
| ［70］ | Reich K, Teixeira HD, de Bruin⁃Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （AD Up）: results from a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2021,397（10290）:2169⁃2181. doi: 10.1016/S0140⁃6736（21）00589⁃4. |
| ［71］ | Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:397⁃402. doi: 10. 1111/jdv.14738. |
| ［72］ | Sardana K, Sharath S, Khurana A. Use of tofacitinib in recalcitrant cases of chronic pruritus of unknown origin［J］. Arch Dermatol Res, 2023,315（10）:2955⁃2957. doi: 10.1007/s00403⁃023⁃02707⁃1. |
| ［73］ | van Huizen AM, Sikkel R, Caron A, et al. Methotrexate dosing regimen for plaque⁃type psoriasis: an update of a systematic review［J］. J Dermatolog Treat, 2022,33（8）:3104⁃3118. doi: 10.1080/09546634.2022.2117539. |
| ［74］ | Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta⁃analysis［J］. Cochrane Database Syst Rev, 2023,7（7）:CD011535. doi: 10.1002/14651858.CD011535.pub6. |
| ［75］ | Chu A, Wong MM, Rayner DG, et al. Systemic treatments for atopic dermatitis （eczema）: systematic review and network meta⁃analysis of randomized trials［J］. J Allergy Clin Immunol, 2023,152（6）:1470⁃1492. doi: 10.1016/j.jaci.2023.08.029. |
| ［76］ | Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta⁃analysis［J］. JAMA Dermatol, 2020,156（6）:659⁃667. doi: 10.1001/jamadermatol. 2020.0796. |
| ［77］ | Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: a systematic review and meta⁃analysis［J］. Allergy, 2021,76（4）:1053⁃1076. doi: 10. 1111/all.14631. |
| ［78］ | Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series［J］. J Dtsch Dermatol Ges, 2008,6（11）:941⁃946. doi: 10.1111/j.1610⁃0387.2008.06745.x. |
| ［79］ | Klejtman T, Beylot⁃Barry M, Joly P, et al. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:437⁃440. doi: 10.1111/jdv.14646. |
| ［80］ | Bergasa NV, McGee M, Ginsburg IH, et al. Gabapentin in patients with the pruritus of cholestasis: a double⁃blind, randomized, placebo⁃controlled trial［J］. Hepatology, 2006,44（5）:1317⁃1323. doi: 10.1002/hep.21370. |
| ［81］ | Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo⁃controlled, double⁃blind trial［J］. Nephrol Dial Transplant, 2004,19（12）:3137⁃3139. doi: 10.1093/ndt/gfh496. |
| ［82］ | Mazza M, Guerriero G, Marano G, et al. Treatment of prurigo nodularis with pregabalin［J］. J Clin Pharm Ther, 2013,38（1）:16⁃18. doi: 10.1111/jcpt.12005. |
| ［83］ | Yue J, Jiao S, Xiao Y, et al. Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double⁃blind study［J］. Int Urol Nephrol, 2015,47（1）:161⁃167. doi: 10.1007/s11255⁃014⁃0795⁃x. |
| ［84］ | Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus［J］. Acta Derm Venereol, 2019,99（5）:469⁃506. doi: 10.2340/00015555⁃3164. |
| ［85］ | Mathur VS, Kumar J, Crawford PW, et al. A multicenter, randomized, double⁃blind, placebo⁃controlled trial of nalbuphine ER tablets for uremic pruritus［J］. Am J Nephrol, 2017,46（6）:450⁃458. doi: 10.1159/000484573. |
| ［86］ | Huang X, Xiao Y, Jing D, et al. Arsenic exposure and pruritus: evidence from observational, interventional, and mendelian randomization studies［J］. Allergy, 2023,78（6）:1585⁃1594. doi: 10.1111/all.15758. |
| ［87］ | Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus［J］. N Engl J Med, 2020,382（3）:222⁃232. doi: 10.1056/NEJMoa1912770. |
| ［88］ | Kim BS, Bissonnette R, Nograles K, et al. Phase 2 trial of difelikefalin in Notalgia paresthetica［J］. N Engl J Med, 2023,388（6）:511⁃517. doi: 10.1056/NEJMoa2210699. |
| ［89］ | Buteau A, Reichenberg J. Psychogenic pruritus and its management［J］. Dermatol Clin, 2018,36（3）:309⁃314. doi: 10. 1016/j.det.2018.02.015. |
| ［90］ | Kouwenhoven TA, van de Kerkhof P, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review［J］. J Am Acad Dermatol, 2017,77（6）:1068⁃1073.e7. doi: 10.1016/j.jaad.2017.08.025. |
| ［91］ | Kaur R, Sinha VR. Antidepressants as antipruritic agents: a review［J］. Eur Neuropsychopharmacol, 2018,28（3）:341⁃352. doi: 10.1016/j.euroneuro.2018.01.007. |
| ［92］ | Ständer S, Böckenholt B, Schürmeyer⁃Horst F, et al. Treatment of chronic pruritus with the selective serotonin re⁃uptake inhibitors paroxetine and fluvoxamine: results of an open⁃labelled, two⁃arm proof⁃of⁃concept study［J］. Acta Derm Venereol, 2009,89（1）:45⁃51. doi: 10.2340/00015555⁃0553. |
| ［93］ | Wachholz PA, Masuda PY, Pinto A, et al. Impact of drug therapy on brachioradial pruritus［J］. An Bras Dermatol, 2017,92（2）:281⁃282. doi: 10.1590/abd1806⁃4841.20175321. |
| ［94］ | Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double⁃blind trial［J］. Nephron, 1994,67（3）:270⁃273. doi: 10.1159/000187978. |
| ［95］ | Sharma D, Kwatra SG. Thalidomide for the treatment of chronic refractory pruritus［J］. J Am Acad Dermatol, 2016,74（2）:363⁃369. doi: 10.1016/j.jaad.2015.09.039. |
| ［96］ | Müller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5⁃hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo⁃controlled, double⁃blind cross⁃over trial［J］. Eur J Gastroenterol Hepatol, 1998,10（10）:865⁃870. doi: 10.1097/00042737⁃199810000⁃00010. |
| ［97］ | Yosipovitch G, Ständer S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo⁃controlled phase 2 clinical trial［J］. J Am Acad Dermatol, 2018,78（5）:882⁃891.e10. doi: 10.1016/j.jaad.2018.02.030. |
| ［98］ | Ständer S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2019,80（5）:1395⁃1402. doi: 10.1016/j.jaad.2019.01.052. |
| ［99］ | Ada S, Seçkin D, Budakoğlu I, et al. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study［J］. J Am Acad Dermatol, 2005,53（1）:149⁃151. doi: 10.1016/j.jaad.2004.12.052. |
| ［100］ | Decock S, Roelandts R, Steenbergen WV, et al. Cholestasis⁃induced pruritus treated with ultraviolet B phototherapy: an observational case series study［J］. J Hepatol, 2012,57（3）:637⁃641. doi: 10.1016/j.jhep.2012.04.023. |
| ［101］ | Kaptanoglu AF, Oskay T. Ultraviolet B treatment for pruritus in Hodgkin′s lymphoma［J］. J Eur Acad Dermatol Venereol, 2003,17（4）:489⁃490. doi: 10.1046/j.1468⁃3083.2003.00614_15.x. |
| ［102］ | Huang D, Chen K, Zhang FR, et al. Efficacy and safety of Run Zao Zhi Yang capsule on chronic eczema: a multiple⁃center, randomized, double⁃blind, placebo⁃controlled clinical study［J］. J Dermatolog Treat, 2019,30（7）:677⁃684. doi: 10.1080/09546634.2019.1571267. |
| ［103］ | Xue W, Zhao Y, Yuan M, et al. Chinese herbal bath therapy for the treatment of uremic pruritus: meta⁃analysis of randomized controlled trials［J］. BMC Complement Altern Med, 2019,19（1）:103. doi: 10.1186/s12906⁃019⁃2513⁃9. |
| ［104］ | Stellon A. Neurogenic pruritus: an unrecognised problem? A retrospective case series of treatment by acupuncture［J］. Acupunct Med, 2002,20（4）:186⁃190. doi: 10.1136/aim.20.4. 186. |
| ［105］ | Chung BY, Um JY, Kim JC, et al. Pathophysiology and treatment of pruritus in elderly［J］. Int J Mol Sci, 2020,22（1）doi: 10.3390/ijms22010174. |
| ［106］ | Balakirski G, Novak N. Atopic dermatitis and pregnancy［J］. J Allergy Clin Immunol, 2022,149（4）:1185⁃1194. doi: 10.1016/j.jaci.2022.01.010. |
| ［107］ | Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1644⁃1659. doi: 10.1111/jdv.15709. |
| ［108］ | Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy［J］. J Am Acad Dermatol, 2014,70（3）:401.e1⁃14; quiz 415. doi: 10. 1016/j.jaad.2013.09.010. |
| ［109］ | Weber⁃Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study［J］. Reprod Toxicol, 2008,26（1）:19⁃23. doi: 10.1016/j.reprotox. 2008.05.053. |
| ［110］ | Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study［J］. J Allergy Clin Immunol, 2003,111（3）:479⁃483. doi: 10.1067/mai.2003.130. |
| ［111］ | Reggia R, Bazzani C, Andreoli L, et al. The efficacy and safety of cyclosporin A in pregnant patients with systemic autoimmune diseases［J］. Am J Reprod Immunol, 2016,75（6）:654⁃660. doi: 10.1111/aji.12514. |
| ［112］ | Pugliese D, Privitera G, Gisbert JP, et al. New drugs for the treatment of IBD during conception, pregnancy, and lactation［J］. Dig Liver Dis, 2024,56（2）:235⁃241. doi: 10.1016/j.dld. 2023.08.054. |
| ［113］ | Janssen NM, Genta MS. The effects of immunosuppressive and anti⁃inflammatory medications on fertility, pregnancy, and lactation［J］. Arch Intern Med, 2000,160（5）:610⁃619. doi: 10.1001/archinte.160.5.610. |
| [1] | 郭澜 晋红中. 治疗瘙痒的小分子/生物制剂药物研究进展[J]. 中华皮肤科杂志, 2024, 57(5): 475-478. |
| [2] | 中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟 中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 426-434. |
| [3] | 中国医师协会皮肤科医师分会 中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417. |
| [4] | 中国中西医结合学会皮肤性病学分会真菌学组 中国耐药皮肤癣菌病诊治与防控工作组. [开放获取] 中国耐药皮肤癣菌感染诊治与防控专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 418-425. |
| [5] | 王煜坤 刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660. |
| [6] | 杨玉婷 顾国林 吴敏娟 盛志杰 李晋 莫星帆 吴敏智 胥萍. 血清纤维连接蛋白联合梅毒非特异性抗体检测在梅毒血清固定患者中排除无症状神经梅毒的初步探讨[J]. 中华皮肤科杂志, 2024, 57(3): 246-249. |
| [7] | 中国医学科学院皮肤病医院 中国疾病预防控制中心性病控制中心 中华医学会皮肤性病学分会性病学组 中国康复医学会皮肤病康复专业委员会. [开放获取] 中国生殖支原体感染诊疗专家共识（2024）[J]. 中华皮肤科杂志, 2024, 57(3): 201-208. |
| [8] | 谢琳 陈锐 牛建军 杨天赐. 新型神经梅毒诊断标志物UCH-L1、GFAP和NF-L与传统神经梅毒检测指标的诊断效能比较[J]. 中华皮肤科杂志, 2024, 57(3): 224-232. |
| [9] | 陈娜娜 李峥 张杰 李世慎 李伟. 南宁市147例隐性梅毒患者中早期感染情况的横断面调查[J]. 中华皮肤科杂志, 2024, 57(3): 213-217. |
| [10] | 中华医学会皮肤性病学分会 中国疾病预防控制中心性病控制中心 中国医师协会皮肤科医师分会 中国康复医学会皮肤病康复专业委员会. 中国沙眼衣原体泌尿生殖道感染临床诊疗指南（2024）[J]. 中华皮肤科杂志, 2024, 57(3): 193-200. |
| [11] | 严可心 张韡 宋昊 徐秀莲. 纳米医学在恶性黑色素瘤中的诊断和治疗新策略[J]. 中华皮肤科杂志, 2024, 0(3): 20230109-e20230109. |
| [12] | 陈立新 王莹 高西波 秦蓓 李钦峰. 儿童经典型和色素减退型扁平疣反射式共聚焦显微镜特征及与组织病理的对应关系初探[J]. 中华皮肤科杂志, 2024, 57(3): 249-253. |
| [13] | 中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟 中国麻风防治协会皮肤性病检验与诊断分会. 中国皮肤非结核分枝杆菌病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 109-118. |
| [14] | 李吉 谢红付. 如何避免玫瑰痤疮的误诊[J]. 中华皮肤科杂志, 2024, 57(2): 119-122. |
| [15] | 那君 李若瑜 仲少敏 杨莉 吴艳. 玫瑰痤疮真实世界诊疗现状调查分析[J]. 中华皮肤科杂志, 2024, 57(2): 127-133. |
|
